Abstract. Chinese medicines are emerging as an attractive new generation of anticancer drugs. Here, we explored the impact of salvianolic acid B (Sal B), the major water-soluble compounds of Danshen, on apoptosis and autophagy of human hepatocellular carcinoma cells (HCC). We also investigated the related molecular mechanisms. We found that Sal B exhibits potent ability to inhibit HCC cells viability in a concentration-dependent manner, and to induce apoptosis via the mitochondrial apoptosis pathway. Additionally, Sal B could also induce autophagy. Furthermore, pretreatment with the autophagy inhibitor chloroquine or 3-methyladenine showed the potential in attenuating the apoptosis rate induced by Sal B. Mechanistically, Sal B treatment inhibited the AKT/mTOR signaling cascade in vitro. Overexpression of AKT abolished the effects of Sal B on HCC cells, suggesting a critical role of the AKT/mTOR signaling pathway in Sal B-induced biological effects. Our results indicated that the mitochondrial pathway was involved in Sal B-induced apoptosis of HCC cells. Moreover, the AKT/mTOR signaling pathway was involved in Sal B-induced autophagy, which promoted apoptosis. This study may provide a promising strategy for using Sal B as a chemotherapeutic agent for patients with HCC.

Introduction

Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and the third cause of cancer mortality (1,2). HCC is associated with infection with hepatitis B and C virus. Most HCC patients are diagnosed at the late stage and lose the opportunity for surgical operation (3). Conventional chemotherapy with oxaliplatin, doxorubicin, and fluorouracil as monotherapy or in combination for patients with advanced HCC is usually ineffective with a low response rate and severe side effects (4-6). Sorafenib, a multitargeted tyrosine kinase inhibitor which has been shown to improve by 2.8 months the median overall survival (OS) and by 2.7 months the median progression-free survival (PFS) for unrespectable HCC (7). Currently, the prognosis of HCC is poor even with multidisciplinary comprehensive treatment. Therefore, identification and development of novel and safe treatment strategies are urgently needed to improve treatment outcomes.

In recent years, Chinese medicine is emerging as an attractive new generation of anticancer drugs due to their ability to effectively eliminate cancer cells with low toxicity (8-10). Salvia miltiorrhiza (Danshen), a popular Chinese herb, has been widely used for treating angina pectoris, myocardial infarction (MI) and stroke (11,12). Salvianolic acid B (Sal B) is one of the major water-soluble compounds and active ingredients of Danshen (13,14). Recently, the anticancer effects of Sal B have been demonstrated in human cancer cell lines including prostate, breast, liver, and head and neck squamous cell cancers (15-17). However, the effects of Sal B on HCC and the antitumor mechanisms have not been adequately studied.

Additionally, studies on the antitumor activity of Sal B have focused on inhibition of proliferation and induction of apoptosis (15). Sal B has also been reported to induce autophagy (18). Understanding the interplay between apoptosis and autophagy induced by Sal B in HCC may identify new targets for cancer therapy and improve the therapeutic efficiency of
growth and induced cell death of human HCC cells in vitro. We also found that autophagy together with apoptosis is involved in Sal B-induced cell death in HCC cells. Inhibition of autophagy attenuated Sal B-induced cell death by reducing apoptosis. Moreover, Sal B-induced cell death was associated with AKT/mTOR signaling inhibition. These results suggest that Sal B could be a potential anticancer agent for the treatment of HCC.

Materials and methods

Chemicals and antibodies. Sal B was purchased from Sigma (Sigma-Aldrich Corp., St. Louis, MO, USA). 3-MA and CQ were purchased from J&K Chemical Ltd. (J&K Chemical Ltd., Beijing, China). JC-1 and LysoTracker Red were obtained from Invitrogen (Guangzhou, China). The primary antibodies against LC-3, p62, Beclin-1, cleaved PARP, cleaved caspase-3, cytochrome c, total or phospho-AKT (Ser473), total or phospho-mTOR (Ser2448), phospho-4EBP1 (Thr70), and phospho-P70S6K (Thr389) were purchased from Cell Signal Technology (Boston, MA, USA). The secondary antibodies were biotin-conjugated anti-rabbit IgG purchased from Cell Signal Technology. The FITC-conjugated anti-rabbit IgG was purchased from Beyotime (Beyotime, Nantong, China).

Cells lines and cultures. SK-Hep-1 and Bel-7404 cells were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). The cell lines were frozen in liquid nitrogen soon after arrival. The experiments with these cells were carried out within 6 generations after resuscitation. SK-Hep-1 and Bel-7404 cells were cultured in Dulbecco's modified Eagle's medium (DMEM), containing 10% fetal bovine serum (FBS), 100 U penicillin and 100 U streptomycin at 37°C in a humidified incubator of 5% CO₂ and 95% air.

Cell viability assay. Cell proliferation was determined by MTS assay. Cells were seeded into 96-well plates and treated with Sal B, CQ, 3-MA or a combination. After treatment, 10 µl MTS (Promega) was added into each well for 2-h incubation. The absorbance was measured using a model ELX800 Microplate Reader (Bio-Tek Instruments, Inc., Winooski, VT, USA) at 490 nm to calculate the proliferation. Three independent experiments were performed to determine the half maximal inhibitory concentration values (IC₅₀).

 Colony forming assay. Cells were incubated at a density of 1,000 cells per well in 6-well plates and treated with a determined dose of Sal B or vehicle control for 2 weeks. After fixation with 4% paraformaldehyde, the colonies formed were counterstained with crystal violet staining solution.

Apoptosis analysis. The cell apoptotic rate was determined by flow cytometry analysis using fluorescein isothiocyanate (FITC) Annexin V Apoptosis Detection kit (KeyGen Biotech, Nanjing, China). Cells were collected by trypsinization, washed twice and resuspended in 1X binding buffer at a concentration of 1x10⁵ cells/ml. Then, 100 µl of cells were mixed with 5 µl of FITC Annexin V and 5 µl PI and incubated for 15 min. The samples were sent out for analysis by flow cytometry. The results were analyzed with the BD FACS Calibur® system.

Immunofluorescence analysis. Cells, seeded at 3x10⁵ into 6-well culture plates, were treated with a determined dose of Sal B for indicated intervals and were incubated with Lyso Tracker for 60 min. Thereafter, cells were washed twice with PBS, followed by fixation in 4% paraformaldehyde and permeabilized with 1% CHAPS buffer (150 mM NaCl, 0.1% HEPES, 1.0% CHAPS) at room temperature for 15 min. Hereafter, cells were incubated with anti-LC3 antibodies for 2 h at 37°C, and incubated with FITC-conjugated anti-rabbit IgG for 1 h at 37°C, and the cell nuclei were stained by DAPI (Invitrogen) for 15 min. Samples were examined under a Zeiss LSM 710 fluorescence microscope system (Carl Zeiss Inc, Dublin, CA, USA). Images were processed with ZEN LE software. For quantification of LC3-positive cells, 150-200 cells were randomly selected from the acquired images and counted. Cells with more than five dots of specific green or yellow signals were considered to be LC3-positive.

Transmission electron microscope. Cells, seeded at 3x10⁵ into 6-well culture plates, were treated with a dose of 200 µM Sal B for 24 h. Then, the cells were washed and fixed for 30 min in 2.5% glutaraldehyde. The samples were treated with 1.5% osmium tetroxide, dehydrated with acetone and embedded in Durcupan resin. Thin sections were stained with lead citrate and examined by Tecnai11 10 electron microscopy (Philips, Eindhoven, The Netherlands) at 60 kV.

RNA interference. For ATG6 (Beclin-1) interference, two siRNA oligonucleotides targeting ATG6 were synthesized by GenePharma (Shanghai, China). The sequences of the sense strands of the RNAs targeting ATG6 used in this study were as follows: ATG6 siRNA-1 (si1): 5'-GUGAGAAGCAAGCCCU UAUUTT-3', ATG6 siRNA-2 (si2): 5'-CUCCAGUGCUAAGCU ACAU-3'. A non-specific oligo that is not complementary to any human genes was used as a negative control. The mixture of si1 and si2 was used to increase the inhibitory activity. Cells were transfected with siRNA using HiPerFect (Qiagen) according to the manufacturer's protocol.

Plasmids transfection. The pcDNA3-AKT-T7 plasmid was a gift from William Sellers (Addgene plasmid 9003). Cells were seeded into 6-well plates the day before transfection. Attractene (Qiagen) was used for transfection according to the manufacturer's protocol. Ater 24 h of incubation, the cells were subjected to different treatments. pcDNA3 empty vectors were used as controls for transfection experiments.

Isolation of cytosolic protein fractions. Cells were seeded in 6-well culture plates at 40-50% confluence. The next day, the cells were incubated with a determined dose of Sal B. Then, the cells were trypsinized, washed twice with ice-cold PBS, and the cytosolic protein fractions were isolated using the Cell Mitochondria Isolation kit (Beyotime) according to the manufacturer's protocol.
Western blot analysis. Western blot analysis was performed as described previously (19). Briefly, proteins (40 µg) were resolved by 6-15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA). The membranes were then blocked in 5% (w/v) skimmed-milk for 1 h, followed by incubation with appropriate primary antibodies (diluted 1:1,000-1:5,000) overnight at 4˚C. Bound antibodies were detected with peroxidase-conjugated goat anti-rabbit or goat anti-mouse secondary antibodies and the blots developed using enhanced chemiluminescence (Millipore). Western blot analysis data were quantified by ImageJ densitometric analysis and normalized by GAPDH.

Statistical analysis. All experiments were performed at least three times, and the data were presented as the mean ± standard deviation. GraphPad Prism 5.0 was used for statistical analysis. A difference was considered significant at P<0.05.

Results

Sal B inhibits growth of HCC cells. We first examined the inhibitory effect of Sal B on viability in HCC cell lines. As shown in Fig. 1A, Sal B significantly inhibited the growth of cancer cells in a dose-dependent manner, with a half maximal inhibitory concentration (IC50) of 143.82 µM for SK-Hep-1 and 240.11 µM for Bel-7404 after 48 h of exposure.
Colony-formation experiments also indicated that Sal B markedly inhibited the growth of HCC cells (Fig. 1B and C). We also investigated the effects of Sal B on the growth of HL-7702 cells (a normal human liver cell line). The results showed that the cytotoxic effect of Sal B on HL-7702 cells (IC₅₀ 758.63 µM) appeared much lower than that observed in SK-Hep-1 and Bel-7404 cells (Fig. 1D).

**Sal B induces apoptotic cell death in HCC cells.** To examine the cell growth inhibition induced by Sal B related to apoptosis, Sal B-treated cells were stained with propidium iodide (PI)/Annexin V-FITC and quantified by flow cytometry. The quantification shown for apoptosis reflected the values for total apoptosis. We also determined whether apoptosis was dose- or time-dependent altered in cells treated with Sal B. Sal B induced a dose- and time-dependent increase of apoptosis in HCC cells (Fig. 2A-C).

Then we measured the mitochondrial membrane potential (∆ψm) by flow cytometry and found that Sal B treatment led to depolarization of ∆ψm in a dose-dependent manner (Fig. 2D).
Western blot analyses showed that cleaved caspase-9, cleaved caspase-3, cleaved poly(ADP-ribose) polymerase (PARP), and cytosolic Cyto c were increased after treatment with Sal B for 24 h (Fig. 2E). The level of cleaved PARP, cleaved caspase-3, cleaved caspase-9, and cytosolic Cyto c increased 2.8-, 3.0-, 2.9- and 2.5-fold, respectively, in SK-Hep-1 cells treated with 200 µM Sal B for 24 h (Fig. 2E). The level of cleaved PARP, cleaved caspase-3, cleaved caspase-9, and cytosolic Cyto c increased 3.4-, 2.7-, 2.4- and 2.8-fold, respectively, in Bel-7404 cells treated with 200 µM Sal B for 24 h (Fig. 2E). These results demonstrated that Sal B induced apoptosis in the HCC cells.

Sal B induces autophagy in HCC cells. Apoptosis and autophagy are highly interactive. To examine whether Sal B could induce autophagy, the treated cells were analyzed by western blot analysis and electron microscopy. The characteristics of autophagosomes are described as double-layer structure with cytoplasmic components. After treatment with Sal B for 24 h, most of the HCC cells displayed an extensive accumulation of double structures with a broad range of morphologies, indicating the formation of autophagosomes (Fig. 3). The significantly increased expression of LC3-II, Beclin-1 and the attenuated expression of p62/SQSTM1 were observed in cells treated with Sal B for 24 h (Fig. 4A). The level of LC3-II and Beclin-1 increased 3.5- and 2.6-fold, respectively, while the level of p62 decreased 70%, in Bel-7404 cells treated with 200 µM Sal B for 24 h (Fig. 4A).

For further confirmation, the cells were incubated with an antibody against microtubule-associated protein 1 light chain 3 (LC3). The punctate LC3 II-labeled autophagolysosome vacuoles were frequently observed in cells treated with Sal B for 48 h compared with their controls (Fig. 4B). Next, we determined whether autophagy was time-dependently altered in cells treated with Sal B. A time-dependent increase of punctate LC3-II dots was observed from 12-, 24- and 48-h in cells treated with Sal B (Fig. 4C).

Interactions between Sal B-induced autophagy and apoptotic cell death in HCC cells. The relationships between autophagy and apoptosis are complicated. There is consensus that the relationships between autophagy and apoptosis are highly depended on the tumor types and stimulus characteristic. To confirm the role of Sal B-induced autophagy in HCC cells promoted or inhibited apoptosis, we treated the cells with the autophagy inhibitor 3-MA and CQ. Addition of 5 mM 3-MA or 5 µM CQ attenuated Sal B-induced apoptosis in HCC cells (Fig. 5A). In addition, siRNAs against Beclin-1 was used to block autophagy. The level of Beclin-1 decreased 70% in SK-Hep-1 cells and 60% in Bel-7404 cells treated with siRNAs
against Beclin-1 (Fig. 5B). Inhibition of autophagy attenuated Sal B-induced apoptosis in HCC cells (Fig. 5B).

Western blot analysis was used to detect the influence of 3-MA pretreatment on cleaved PARP and cleaved caspase-3 expression induced by Sal B. Autophagy level was found to significantly decrease after 3-MA pretreatment, and the expressions of cleaved PARP and cleaved caspase-3 also decreased (Fig. 5C). The level of cleaved PARP, cleaved caspase-3, and LC3-II decreased from 4.5- to 2.1-, 2.7- to 1.9- and 5.5- to 1.6-fold, respectively, in SK-Hep-1 cells treated with 200 µM Sal B and the combination of Sal B and 3-MA for 24 h (Fig. 5C). The level of cleaved PARP, cleaved caspase-3, and LC3-II decreased from 3.4- to 2.5-, 3.1- to 2.2- and 4.2- to 1.2-fold, respectively, in Bel-7404 cells treated with 200 µM Sal B and...
the combination of Sal B and 3-MA for 24 h (Fig. 5C). All the results demonstrated that the inhibition of autophagy in HCC cells had the potential of attenuating Sal B-induced apoptosis.

**AKT/mTOR signaling pathway is involved in Sal B-induced autophagy in HCC cells.** AKT/mTOR signaling pathway is the key regulatory molecule of both autophagy and apoptosis. Therefore, we investigated whether the AKT/mTOR pathway played a central role in Sal B-mediated cell death. Western blot analysis confirmed that the levels of phosphorylated AKT, mTOR and its downstream effector p70S6K and p-4EBP1 were significantly reduced by Sal B (Fig. 6A). The level of phosphorylated AKT, mTOR, p70S6K and p-4EBP1 decreased 70, 70, 70 and 60%, respectively, in SK-Hep-1 cells treated with 200 µM Sal B for 24 h (Fig. 6A). The level of phosphorylated AKT, mTOR, p70S6K and p-4EBP1 decreased 70, 80, 70 and 70%, respectively, in Bel-7404 cells treated with 200 µM Sal B for 24 h (Fig. 6A).

To further identify the role of AKT in Sal B-induced biological effects, HCC cells were transiently transfected with pcDNA3-AKT-T7 plasmid. The level of phosphorylated AKT and total AKT increased 2.0- and 5.5-fold in SK-Hep-1 cells, while 1.6- and 5.2-fold in Bel-7404 cells transfected with pcDNA3-AKT-T7 plasmid (Fig. 6D). As shown in Fig. 6B-D, enforced expression of AKT significantly attenuated Sal B-induced growth inhibition, and apoptosis. Furthermore, Sal B-induced autophagy was also decreased in the transfected cells (Figs. 6D and 7). The level of cleaved PARP and LC3-II decreased from 2.6- to 1.4- and 2.2- to 1.3-fold, respectively, in SK-Hep-1 cells treated with 200 µM Sal B and the combination of Sal B and pcDNA3-AKT (Fig. 6D). The level of cleaved PARP and LC3-II decreased from 2.7- to 1.5- and 1.8- to 1.2-fold, respectively, in Bel-7404 cells treated with 200 µM Sal B and the combination of Sal B and pcDNA3-AKT (Fig. 6D). These results suggested that overexpression of AKT can override the Sal B-induced
biological effects in HCC cells. Taken together, these data demonstrate that AKT is a critical mediator in regulating Sal B-mediated biological effects.

**Discussion**

Currently, the prognosis of HCC is poor even with multidisciplinary comprehensive treatment, and recurrence rate is >50% (20, 21). There is an urgent need for development of efficacious therapies. Growing evidence indicates that Chinese medicine plays a promising role in developing novel anticancer drugs. Understanding the anti-neoplastic mechanisms of Chinese medicine may help improve the efficacy of these agents.

In this study, we demonstrated that Sal B markedly inhibited the proliferation of HCC cells. We also showed that Sal B induced mitochondria-mediated apoptosis in HCC cells, accompanied by a decrease of mitochondrial potential, and increase of cytosol cytochrome c. Release of cytochrome c from the mitochondria into cytosol activates intrinsic apoptosis (22). Cytosolic Cyto c initiates the apoptotic process by activating a downstream cascade of caspases through processing of procaspase-9 (23). In accord with our findings, some researchers reported that Sal B inhibited the growth of cancer cells through induction of apoptosis (24, 25).

Both apoptosis and autophagy are crucial mechanisms regulating cell survival (26). We thus examined whether Sal B induced autophagy. Autophagy is a tightly regulated intracellular self-digestive process involving the lysosomal degradation of cytoplasmic organelles and proteins (27, 28). In this process, cells digest their own cellular contents by lysosomal degradation and recycle the ingredients to maintain cell survival (29-31). Our data revealed that Sal B could induce autophagy accompanied by apoptosis in HCC cells. Apoptosis and autophagy could be induced by the same stimulus, but the interaction between them was still unclear. In our study, we found that suppression of autophagy by pharmacological inhibitors (3-MA and CQ) or Beclin-1 siRNA...
decreased Sal B-induced apoptosis in HCC cells, revealing that the autophagy induced by Sal B promoted HCC cell apoptosis. These results were consistent with the findings of Kim et al. (32), who reported that the inhibition of autophagy decreased docosahexaenoic acid-induced apoptosis in non-small cell lung cancer cells, indicating that autophagy was a prerequisite for apoptotic cell death. Autophagy can inhibit, delay or promote apoptosis (33-35). The mechanisms of autophagy promoting apoptosis may include upregulation of cells susceptible to drug-induced apoptosis and activating of caspases (36,37). In this study, our data showed that apoptosis level was significantly increased with upregulation of autophagy level. We hypothesize that Sal B could trigger apoptosis and autophagy simultaneously, whereas autophagy increased HCC cells susceptible to Sal B-induced apoptosis. Inhibition of autophagy could significantly reduce the extent of Sal B-induced apoptosis. The interaction between autophagy and apoptosis is extremely complex and needs further investigation.

The molecular mechanism mediating apoptosis and autophagy are complicated. Increasing evidence indicates that autophagy and apoptosis share many common regulatory molecules, such as AKT/mTOR signaling pathway (38). It is well known that the AKT/mTOR pathway plays an important role in cell growth, survival, differentiation and metabolism (39). The aberrant activation of AKT/mTOR signaling pathway contributes to a poor prognosis and plays a critical role in carcinogenesis of HCC (40). Inhibition of AKT/mTOR signaling pathway causes cell death associated with apoptosis and autophagy (41). The downstream target of Akt/mTOR pathway can potently block Bad-induced apoptosis by phosphorylation of Bad at S136 site to disrupt Bad’s binding to Bcl-XL and/or Bcl-2. Thus, inhibition of Akt/mTOR pathway possibly increases apoptosis (42).

Our results show that Sal B treatment decreases AKT/mTOR pathway activity. This inhibitory effect was correlated with the decrease of phosphorylation of AKT, mTOR and their downstream targets, p70S6K and 4E-BP1. Overexpression of AKT abolished the effects of Sal B on HCC cells. These findings indicate that Sal B induces apoptosis and autophagy in HCC cells through inhibition of the AKT/mTOR signaling pathway. Moreover, the appearance of apoptosis and autophagy after Sal B treatment is closely linked to the inhibition of AKT/mTOR pathway, demonstrating this pathway plays a pivotal role in HCC treatment.

In conclusion, our results demonstrate for the first time that Sal B suppressed cell proliferation and induces autophagy and apoptosis in HCC cells through the AKT/mTOR pathway.
Sal B could act as a new anticancer agent for HCC by inducing apoptosis and autophagy. These results will expand our knowledge of the anticancer molecular mechanisms of Sal B and the interaction between autophagy and apoptosis.

Acknowledgements

This study was supported by the grants from Medical Health Research Project of Zhejiang province (2015YK3B031); Science and Technology Planning Project of Hangzhou (20150733Q20); Health Science and Technology Plan Projects of Hangzhou (2014A11); Science and Technology Planning Project of Wenzhou (2015Y0395).

References